
Cancer and rare diseases drugmaker Springworks Therapeutics' SWTX.O shares surge, up about 30% to $52.70 in morning trade
Reuters reports that German healthcare and technology group, Merck KGaA MRCG.DE is in advanced talks to acquire SWTX, according to people familiar with the matter
If the talks are successful, a deal could be signed in the coming weeks, according to Reuters' sources
Both Springworks and Merck declined to comment
SWTX stock has risen 12% in the last 12 months